Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small-cell lung cancer with a PD-L1 expression level of ≥1% by the USA Food and Drug Administration

G Mountzios; J Remon; S Novello; N Blais; R Califano; T Cufer; A M Dingemans; S V Liu; N Peled; N A Pennell; M Reck; C Rolfo; D Tan; J Vansteenkiste; H West; B Besse

doi:10.1093/annonc/mdz295

Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small-cell lung cancer with a PD-L1 expression level of ≥1% by the USA Food and Drug Administration

Ann Oncol. 2019 Nov 1;30(11):1686-1688. doi: 10.1093/annonc/mdz295.

Authors

G Mountzios¹, J Remon², S Novello³, N Blais⁴, R Califano⁵, T Cufer⁶, A M Dingemans⁷, S V Liu⁸, N Peled⁹, N A Pennell¹⁰, M Reck¹¹, C Rolfo¹², D Tan¹³, J Vansteenkiste¹⁴, H West¹⁵, B Besse¹⁶

Affiliations

¹ Department of Medical Oncology, Henry Dunant Hospital Center, Athens, Greece. Electronic address: [email protected].
² Department of Medical Oncology, CIOCC HM Delfos Hospital, Barcelona, Spain.
³ Department of Oncology, University of Turin, AOU San Luigi, Orbassano, Italy.
⁴ Centre Hospitalier Universitaire de Montréal, University of Montreal, Montreal, Canada.
⁵ Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester; Division of Cancer Sciences, University of Manchester, Manchester, UK.
⁶ University Clinic Golnik, Medical Faculty Ljubljana, Slovenia.
⁷ Department of Respiratory Medicine, Maastricht University Medical Center, Maastricht and Erasmus Medical Center, Rotterdam, The Netherlands.
⁸ Lombardi Comprehensive Cancer Center, Georgetown University, Washington, USA.
⁹ Soroka Medical Center and Ben-Gurion University, Beer-Sheva, Israel.
¹⁰ Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, USA.
¹¹ Lung Clinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf, Germany.
¹² Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, USA.
¹³ Division of Medical Oncology, National Cancer Centre, Singapore.
¹⁴ Respiratory Oncology Unit, University Hospital KU Leuven, Leuven, Belgium.
¹⁵ Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, USA.
¹⁶ Cancer Medicine Department, Institut Gustave Roussy, Villejuif; Université Paris-Saclay, Orsay, France.

PMID: 31504132
DOI: 10.1093/annonc/mdz295

No abstract available

Publication types

Editorial
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Monoclonal, Humanized / pharmacology
Antibodies, Monoclonal, Humanized / therapeutic use*
B7-H1 Antigen / antagonists & inhibitors
B7-H1 Antigen / immunology
B7-H1 Antigen / metabolism*
Carcinoma, Non-Small-Cell Lung / drug therapy*
Carcinoma, Non-Small-Cell Lung / immunology
Carcinoma, Non-Small-Cell Lung / mortality
Carcinoma, Non-Small-Cell Lung / pathology
Disease-Free Survival
Drug Approval
Humans
Lung Neoplasms / drug therapy*
Lung Neoplasms / immunology
Lung Neoplasms / mortality
Lung Neoplasms / pathology
Progression-Free Survival
Randomized Controlled Trials as Topic
Standard of Care
Vereinigte Staaten
United States Food and Drug Administration / standards

Substances

Antibodies, Monoclonal, Humanized
B7-H1 Antigen
CD274 protein, human
pembrolizumab